1. Home
  2. HUBS vs HALO Comparison

HUBS vs HALO Comparison

Compare HUBS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HubSpot Inc.

HUBS

HubSpot Inc.

HOLD

Current Price

$232.31

Market Cap

12.0B

Sector

Technology

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$107.72

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBS
HALO
Founded
2005
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
12.0B
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
HUBS
HALO
Price
$232.31
$107.72
Analyst Decision
Strong Buy
Buy
Analyst Count
32
11
Target Price
$435.19
$78.64
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
855.56
N/A
EPS
1.47
3.11
Revenue
$375,612,000.00
$151,862,000.00
Revenue This Year
$20.46
$28.24
Revenue Next Year
$16.01
$12.56
P/E Ratio
$163.35
$34.83
Revenue Growth
N/A
N/A
52 Week Low
$169.63
$61.23
52 Week High
$525.51
$111.15

Technical Indicators

Market Signals
Indicator
HUBS
HALO
Relative Strength Index (RSI) 48.17 65.32
Support Level $229.01 $103.47
Resistance Level $256.77 N/A
Average True Range (ATR) 10.35 2.51
MACD -1.74 -0.83
Stochastic Oscillator 6.75 55.60

Price Performance

Historical Comparison
HUBS
HALO

About HUBS HubSpot Inc.

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: